Chicago – June 13, 2024 – Cooley advised Tempus AI, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its $410.7 million initial public offering (IPO). Tempus offered 11,100,000 shares of its Class A common stock priced at $37 per share, with a 30-day option for the underwriters to purchase up to 1,665,000 additional shares of its Class A common stock at the IPO price, less underwriting discounts and commissions. Tempus’ common stock will begin trading on the Nasdaq Global Select Market on June 14, 2024, under the ticker symbol TEM. The offering is expected to close on June 17, 2024, subject to the satisfaction of customary closing conditions.
Chicago partners Christina Roupas and Courtney Tygesson led the Cooley team, which also included Richard Segal and Eric Jensen.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.